Drug acetylation in breast cancer.
The acetylator phenotype was determined in 100 patients with breast cancer and 100 control female subjects using isoniazid. The proportion of fast acetylators in the breast cancer patients (43%) was not significantly different from the control group (43%). We conclude that acetylator phenotype is unlikely to be an important determinant of the risk of developing breast cancer.
Webster
D J
DJ
Department of Surgery, University of Wales College of Medicine, Llandough Hospital, Penarth, South Glamorgan, UK.
Flook
D
D
Jenkins
J
J
Hutchings
A
A
Routledge
P A
PA
D000107:Acetylation; D001943:Breast Neoplasms / Q000378:metabolism*; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000378:metabolism*
D007538:Isoniazid